Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh
Brief Summary: The investigators aim to establish the non-inferiority of concomitant administration of measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of measles seroconversion rates. The primary study hypothesis is the measles seroconversion rate as defined by the percentage of children seroconverting to measles with a measles serum antibody concentration of \>=1:120 at 8 weeks post vaccination after the concomitant administration of measles-rubella and rotavirus vaccines is non-inferior to that obtained when measles-rubella vaccine is given alone in children 9 months of age who have received a primary rotavirus vaccine series with the first dose between 6 and 10 weeks and the second at least 4 weeks later and are seronegative for measles antibody in the pre-vaccination sample.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
B: Arm Label: measles-rubella and rotavirus vaccines; Type: EXPERIMENTAL; Interventions: Biological: Rotarix vaccine, Biological: measles-rubella vaccine | Arm Label: measles-rubella vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: measles-rubella vaccine | Intervention Type: BIOLOGICAL; Name: Rotarix vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines | Intervention Type: BIOLOGICAL; Name: measles-rubella vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines, measles-rubella vaccine
C: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld
D: Arm Label: PLACEBO-ROTARIX-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: ROTARIX-PLACEBO-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP, PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP

Answer: B